



Contents lists available at ScienceDirect

# International Journal of Biological Macromolecules

Journal homepage: [www.elsevier.com/locate/ijbiomac](http://www.elsevier.com/locate/ijbiomac)



## Review

# Affibody molecules for molecular imaging and targeted drug delivery in the management of breast cancer

Anindita De<sup>a,1</sup>, Gowthamarajan Kuppusamy<sup>a,1</sup>,  
Veera Venkata Satyanarayana Reddy Karri

<sup>a</sup>JSS College of Pharmacy, Dotacamund, Jagadguru Sri Shivarathreeswara University, Mysuru, Karnataka, India

## ARTICLE INFO

### Article history:

Received 24 February 2017

Received in revised form 9 September 2017

Accepted 17 September 2017

Available online xxx

### Keywords:

Breast cancer

Affibody

Drug targeting

## ABSTRACT

Breast cancer is one of the leading reasons for the morbidity and mortality of cancer related death globally. The modern therapies are basically the combination of the breast-preserving surgeries or ablation with or without node biopsy or destroying the carcinoma cells adjuvant with chemotherapy, radiotherapy, hormonal or biological therapies depending upon the nature of the receptor of the cancerous cells, nature of the lymph node, as well as the tendency of the recurrence. For decade's carcinoma management suffered by the limitation of imagining, targeting and penetrability problem associated with management and cure of this deadly disease leads to unwanted chemo-toxicity and side effects. Alike other antibody mimetics, affibodies are designed with the combinatorial protein engineering approaches which are small and robust protein scaffolds retaining the favorable folding and stability. Affibody is one of the significantly important tools for imaging and diagnosis of the affinity specific over expressed proteins in the breast cancer management. The review summarizes the various affibody strategies uses in the management of breast cancer.

© 2017 Elsevier B.V. All rights reserved.

## Contents

1. Breast cancer epidemiology .....	00
1.1. Pathophysiology of breast cancer .....	00
1.2. Current treatment strategies for the Breast cancer and their limitations .....	00
2. Pharmaceutical nanotechnology for treating breast cancer .....	00
2.1. Active and passive targeting in breast cancer management .....	00
2.1.1. Passive targeting .....	00
2.1.2. Active targeting .....	00
3. Affibody and its origin .....	00
3.1. Affibody selection criteria .....	00
3.2. Advantages of Affibody over the other targeting molecules .....	00
4. Role of affibody molecules for breast cancer management .....	00
4.1. Imaging .....	00
4.2. Therapeutic application .....	00
4.2.1. Lipid conjugated affibody .....	00
4.2.2. Affinity probes .....	00
4.2.3. Polymeric nanoparticles affibody .....	00
4.2.4. Bio-affibody molecules .....	00
4.2.5. Computerized approach .....	00
5. Conclusion and outlook .....	00
References .....	00

### • Corresponding authors.

E-mail addresses: [aninditanirupa@gmail.com](mailto:aninditanirupa@gmail.com) (A. De),

[gowthamsang@jssuni.edu.in](mailto:gowthamsang@jssuni.edu.in) (G. Kuppusamy).

<sup>1</sup> These authors contributed equally.

<http://dx.doi.org/10.1016/j.ijbiomac.2017.09.059>

0141-8130/© 2017 Elsevier B.V. All rights reserved.